RxDoctor Payments Data

David Green, MD

Internal Medicine · Dallas, TXNPI 1053335844

Payments from drug & device makers

$304in general payments, 2019–2025

Across 16 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$88
  • Otsuka America Pharmaceutical, Inc.$55
  • Lundbeck LLC$47
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$42
  • Aimmune Therapeutics, Inc.$40
  • Avanir Pharmaceuticals, Inc.$19
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$304 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$228,354
Medicare patients
261
Services billed
2,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban283$134,196
NuplazidPimavanserin Tartrate20$104,606
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,420
NuedextaDextromethorphan Hbr/Quinidine45$19,149
TradjentaLinagliptin66$14,946
Memantine Hcl394$12,508
JardianceEmpagliflozin31$12,277
XareltoRivaroxaban33$10,637
Atorvastatin Calcium734$7,834
NamzaricMemantine Hcl/Donepezil Hcl11$6,243
BrilintaTicagrelor13$5,527
MyrbetriqMirabegron11$5,382
Levothyroxine Sodium690$5,348
Potassium Chloride280$4,636
Pantoprazole Sodium373$4,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$19$19,14945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →